PMC:7534795 / 50943-51970
Annnotations
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T82 | 256-261 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T384 | 122-130 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T385 | 380-388 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T386 | 563-571 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T387 | 646-654 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T388 | 833-841 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T389 | 842-851 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T310 | 111-115 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
| T311 | 487-488 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T312 | 529-530 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T47 | 997-1001 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T95 | 513-524 | http://purl.obolibrary.org/obo/GO_0006412 | denotes | translation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T419 | 0-188 | Sentence | denotes | Currently, there are multiple in vitro experiments and preclinical studies being performed around the world to test novel COVID-19 therapies, which are quickly moving into clinical trials. |
| T420 | 189-338 | Sentence | denotes | Importantly, the early efficacy results have been limited to small-scale clinical studies in which the safety profiles have not been well-identified. |
| T421 | 339-463 | Sentence | denotes | The safety profiles will be critical for COVID-19 patients with underlying comorbidities such as cardiovascular dysfunction. |
| T422 | 464-625 | Sentence | denotes | Therefore, as there is a need for rapid clinical translation and a wide use of novel therapies for COVID-19, continued attention to safety profiles is important. |
| T423 | 626-777 | Sentence | denotes | The rapid spread of COVID-19 globally continues to impact susceptible populations, like elderly patients and individuals with underlying comorbidities. |
| T424 | 778-1027 | Sentence | denotes | While underlying cardiovascular issues are impacted by COVID-19 infection, many existing and novel therapeutic strategies have direct adverse cardiovascular effects, highlighting the importance for consideration in new drug research and development. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1527 | 389-397 | Species | denotes | patients | Tax:9606 |
| 1528 | 722-730 | Species | denotes | patients | Tax:9606 |
| 1529 | 122-130 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1530 | 380-388 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1531 | 436-462 | Disease | denotes | cardiovascular dysfunction | MESH:D002318 |
| 1532 | 563-571 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1533 | 646-654 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1534 | 833-841 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1535 | 842-851 | Disease | denotes | infection | MESH:D007239 |